National Cancer InstituteU.S. National Institutes of
Center to Reduce Cancer Health Disparities logo

CPRCHD's Objectives and Target Areas

The CPRCHD partnerships support the planning and/or implementation of programs that address the following general objectives:

  1. The institutions must form synergistic partnerships that will result in mutual benefits and demonstrate that the specific objectives they wish to achieve within the first three general objectives above either are, dependent upon the partnership for their eventual success or will be achieved faster because of the partnership. Partners must also be willing to work and share their approaches with each other and with other NCI Cancer Centers and other networks supported by the NCI.

    Unlike existing partnerships between USIs and research intensive institutions, this concept is based on the idea of a "True Partnership" where both institutions profit and gain mutual benefits. Furthermore, this concept is based on long-term infrastructure support and the requirement of limited projects/program support to compete for "traditional" NIH/NCI peer-reviewed grant and funding of minority scientists and scientists at USI and projects/programs that focus on cancers, which disproportionately affect minority and underserved populations.

  2. Each partnership emphasizes the four target areas of cancer research, cancer training, and cancer outreach, with cancer education as an optional area:
    (1) Cancer RESEARCH, the partnership must develop joint pilot and full research projects that may be in any area of basic, clinical, translational, prevention, control, behavioral or population research. CPRCHD investigators are encouraged to develop research proposals in emerging technologies. Research projects conducted primarily at the USI may be in any area of cancer research, but research projects conducted primarily at the Cancer Center must specifically address areas of cancer disparity in minority and underserved populations. The expectation is that successful pilot research projects will become full research projects or competitive grant proposals at NIH or other agencies. The full research projects are expected to become competitively funded grants (e.g., R03, R21, R01; project on a P01, P50 and U01).
    (2) Cancer RESEARCH TRAINING, where training and career development programs can be in any of the research areas above but must focus on developing joint programs between USI and Cancer Center(s). These programs should emphasized two aspects: (a) the training of minority scientists and (b) the recognition and understanding (by minority and non-minority trainees alike) of the issues and problems associated with cancer disparities in racial and ethnic minority and socio-economically disadvantaged populations. The CPRCHD requires career development plans for less experienced investigators involved in the partnership from the MSI and the CC. The objective of this endeavor is to increase the chances that junior investigators develop the research skills and abilities needed to work in a collaborative and competitive environment and will eventually become successful independent cancer researchers. The career development plan should ensure that mentors are available to provide appropriate guidance throughout the duration of the program and the CPRCHD application should provide compensation for mentors, co-mentors, and/or consultants. The NCI particularly encourages training of scientists in basic, clinical, translational, behavioral, population and cancer health disparities research, i.e. in the fields of study that are highly dependent for their success on the cultural sensitivity of investigators. Training programs in emerging technologies such as nanotechnology, imaging, proteomics, and genomics are a priority for NCI as there is a huge deficit of scientists from underserved groups engaged in these research areas. These training programs must represent true collaborations that function seamlessly across the institutional boundaries of the USI and the Cancer Center. Successful activities in this area may lead to the submission of a competitive training grant application (e.g. T32; K12; R25T) as well as individual predoctoral fellowships (F31), individual post-doctoral fellowships (F32), career development awards (K01ís, K07ís, K08ís, K23ís, K22ís, K99/R00ís) and research diversity supplements for trainees.
    (3) Cancer OUTREACH, where outreach programs may be defined as proactive efforts to help minority and the underserved communities develop and manage their own culturally sensitive programs for educating their populations about cancer risk, early detection, screening, prevention, and treatment; and MSIs and Cancer Centers would be expected to combine their expertise in working with minority leaders and community organizations to develop outreach programs. These programs must effectively reach individuals, physicians and health care providers and should that increase the recruitment and retention of racial and ethnic minorities and socio-economically disadvantage population into clinical trials such as prevention, early detection or treatment trials. Successful projects could compete for U01ís (Community Network Programs), U10 (MBCCOP).
    (4) Cancer EDUCATION programs could focus on any effort to augment existing or create new curricula in the MSI and/or the Cancer Center. This new curricula would apprise and culturally sensitize graduate and postdoctoral students in research, medicine and public health of the need to reduce the disproportionate cancer burden in racial and ethnic minority and socio-economically disadvantaged populations. A successful effort may result in proposals to compete to the NCI Education Grant Program (R25) and later to institutional commitments to make these curricula an inherent component of their educational systems.
  3. Each partnership includes the following unique features:
    (1) Equality of the partners who are required to submit separate applications.
    (2) Utilization of the Cooperative Agreement mechanism that allows substantial programmatic involvement. This not only provides appropriate evaluation and advice, but also insures the success of the collaborations and partnerships.
    (3) Participation of an institution (whether an MSI or CC) is limited to no more than ONE U54 application.
    (4) Concrete commitment from institutional leadership is required. There must be a common planning, priority setting, and evaluation shared between the partners; and all projects and programs must have co-leadership from the MSI and the Cancer Center.

Updated: 08/05/10